• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Circulating levels of growth hormone in postural orthostatic tachycardia syndrome (Johansson et al. 2021)

Cipher

Administrator
Messages
838
Circulating levels of growth hormone in postural orthostatic tachycardia syndrome
Abstract
Postural orthostatic tachycardia syndrome (POTS) is a cardiovascular autonomic disorder with poorly understood etiology and underlying pathophysiology. Since cardiovascular morbidity has been linked to growth hormone (GH), we studied GH levels in patients with POTS. We conducted an age-sex-matched case–control study in patients with POTS (age 31 ± 9 years; n = 42) and healthy controls (32 ± 9 years; n = 46). Plasma GH levels were measured using high-sensitivity chemiluminescence sandwich immunoassay. The burden of orthostatic intolerance symptoms was assessed by the Orthostatic Hypotension Questionnaire (OHQ), consisting of a symptom assessment scale (OHSA) and a daily activity scale (OHDAS). POTS patients had significantly higher composite OHQ score than controls, more symptoms and less activity. Supine heart rate and diastolic blood pressure (BP), but not systolic BP, were significantly higher in POTS. Median plasma GH levels were significantly lower in POTS (0.53 ng/mL) than controls (2.33 ng/mL, p = 0.04). GH levels were inversely related to OHDAS in POTS and supine systolic BP in POTS and controls, but not heart rate neither group. POTS is associated with lower GH levels. Impairment of daily life activities is inversely related with GH in POTS. A higher supine diastolic BP is inversely associated with GH levels in POTS and healthy individuals.
 
Messages
42
0.53 ng/mL in POTS patients compared to 2.33 ng/mL in controls is a very significant difference.

A small difference might be explained by different activity levels. A nearly 5X difference is difficult to explain away, though.
 

Pyrrhus

Senior Member
Messages
4,172
Location
U.S., Earth
Great paper, thanks for sharing it @Cipher ! :thumbsup:

Is it possible to update the thread title to include the author and year, something like:
"Circulating levels of growth hormone in postural orthostatic tachycardia syndrome (Johansson et al., 2021)"

It's always nice to have this little bit of extra information when searching through old threads for a specific publication...
 

Cipher

Administrator
Messages
838
Great paper, thanks for sharing it @Cipher ! :thumbsup:

Is it possible to update the thread title to include the author and year, something like:
"Circulating levels of growth hormone in postural orthostatic tachycardia syndrome (Johansson et al., 2021)"

It's always nice to have this little bit of extra information when searching through old threads for a specific publication...

Consider it done! :)